Pharmacological inhibition of bromodomain and extra-terminal proteins induces NRF-2-mediated inhibition of SARS-CoV-2 replication and is subject to viral antagonism

ABSTRACT
Inhibitors of bromodomain and extra-terminal proteins (iBETs), including JQ-1, have been suggested as potential therapeutics against SARS-CoV-2 infection. However, molecular mechanisms underlying JQ-1-induced antiviral activity and its susceptibility to viral antagonism remain incompletely understood. iBET treatment transiently inhibited infection by SARS-CoV-2 variants and SARS-CoV, but not MERS-CoV. Our functional assays confirmed JQ-1-mediated downregulation of ACE2 expression and multi-omics analysis uncovered induction of an antiviral NRF-2-mediated cytoprotective response as an additional antiviral component of JQ-1 treatment. Serial passaging of SARS-CoV-2 in the presence of JQ-1 resulted in predominance of ORF6-deficient variants. JQ-1 antiviral activity was transient in human bronchial airway epithelial cells (hBAECs) treated prior to infection and absent when administered therapeutically. We propose that JQ-1 exerts pleiotropic effects that collectively induce a transient antiviral state that is ultimately nullified by an established SARS-CoV-2 infection, raising questions on their clinical suitability in the context of COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Subject Area
- Biochemistry (10379)
- Bioengineering (7695)
- Bioinformatics (26372)
- Biophysics (13547)
- Cancer Biology (10720)
- Cell Biology (15460)
- Clinical Trials (138)
- Developmental Biology (8509)
- Ecology (12842)
- Epidemiology (2067)
- Evolutionary Biology (16885)
- Genetics (11416)
- Genomics (15493)
- Immunology (10638)
- Microbiology (25254)
- Molecular Biology (10239)
- Neuroscience (54587)
- Paleontology (402)
- Pathology (1671)
- Pharmacology and Toxicology (2899)
- Physiology (4355)
- Plant Biology (9263)
- Synthetic Biology (2561)
- Systems Biology (6789)
- Zoology (1470)